Abstracts tagged "interstitial lung disease"

Abstract Number: 528 • 2018 ACR/ARHP Annual Meeting
Progression in Interstitial Lung Disease – Comparison of Rheumatoid Arthritis with Idiopathic Pulmonary Fibrosis
Shirish Dubey¹ and Felix Woodhead², ¹Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²Respiratory Medicine, Glenfields Hospital, Leicester, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) is a common autoimmune condition characterised by symmetrical inflammatory small joint polyarthropathy and loss of function. Systemic manifestations of RA are…
Abstract Number: 791 • 2018 ACR/ARHP Annual Meeting
Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
Rick Silver¹, Ilia Atanelishvili², Tanjina Akter², Kelley Kajdasz³, Dulaney Wilson⁴, Paul J. Nietert⁵, J. Terrill Huggins⁶, Kristin B. Highland⁷ and Galina S. Bogatkevich², ¹Rheumatology, Medical University of SC, Charleston, SC, ²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁵Public Health Science, Medical University of South Carolina, Charleston, SC, ⁶Pulmonology, Medical University of South Carolina, Charleston, SC, ⁷Rheumatology.org, Cleveland Clinic, Cleveland, OH
Background/Purpose: Studies from our laboratory and others have shown thrombin to be a fibrogenic mediator implicated in the pathogenesis of ILD, including scleroderma-associated ILD (SSc-ILD).…
Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Anna-Maria Hoffmann-Vold¹, Toby Maher², Edward Philpot³, Ali Ashrafzadeh⁴, Diwakar Jha⁵, Margarida Alves⁶ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Royal Brompton Hospital, London, United Kingdom, ³IQVIA, Durham, NC, ⁴IQVIA, Los Angeles, CA, ⁵IQVIA, Gurugram, India, ⁶Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…
Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Jeffrey A. Sparks¹, Tracy Doyle², Jie Huang¹, Beatrice Pan², Elaine Fletcher², Ritu Gill³, Hiroto Hatabu², Mizuki Nishino⁴, David Murphy², Taysir Mahmoud², Christine K Iannaccone⁵, Michelle Frits², Bing Lu⁶, Ivan O. Rosas⁷, Paul Dellaripa², Michael E Weinblatt⁵, Elizabeth Karlson⁶ and Nancy A. Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Beth-Israel Deaconess Medical Center, Boston, MA, ⁴Dana-Farber Cancer Institute, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁷BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…
Abstract Number: 1013 • 2018 ACR/ARHP Annual Meeting
Circulating Hybrid M1/M2 Monocytes/Macrophages in Systemic Sclerosis Patients with Lung Involvement
Maurizio Cutolo¹, Amelia Chiara Trombetta², Veronica Tomatis³, Sabrina Paolino⁴, Carmen Pizzorni¹, Vanessa Smith⁵, Paola Contini⁶, Paola Montagna³, Renata Brizzolara² and Stefano Soldano³, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by immune system alterations, vasculopathy and fibrosis [1]. SSc-related interstitial lung disease (ILD) represents a common…
Abstract Number: 1309 • 2018 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features: Is It Frequent?
John Fredy Jaramillo Gallego¹, Marina Scolnik², Joaquin Maritano Furcada³, Maria Laura Acosta Felquer⁴, Nicolas Martin Marin Zucaro¹, Luciano Fernando Lo Giudice¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Pneumology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ⁴Rheumatology Unit, Internal Medicine Service,, Hospital Italiano de Buenos Aires, Capital Federal, Argentina
Background/Purpose: A particular subset of interstitial pneumonia, associated to one or more clinical and serological features, suggesting a possible underlying autoimmune disorder, has been described…
Abstract Number: 1331 • 2018 ACR/ARHP Annual Meeting
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Yves Allenbach¹, Yurdagul Uzunhan², Ségolène Toquet³, Gaëlle Leroux⁴, Laure Gallay⁵, Aude Rigolet⁶, Baptiste Hervier⁶, Nicolas Champtiaux⁶, Mathieu Vautier⁶, Perrine Guillaume⁶, Nicolas Limal⁷, Alain Meyer⁸, Christophe Deligny⁹, Bernard Bonnotte¹⁰, Hervé Devilliers¹¹, Sylvain Audia¹², Maxime Samson¹³, Amélie Servettaz¹⁴, Nathalie Costedoat¹⁵, David Saadoun¹⁶, elisabeth diot¹⁷, Alice Berezne¹⁸, Arsène Mékinian¹⁹, Kuberaka Mariampillai²⁰, Hilario Nunes² and Olivier Benveniste⁶, ¹Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ²Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ³Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ⁴Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁵Internal Medicine, Université de Lyon - CHU Lyon, Lyon, France, ⁶Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ⁷Internal Medicine, APHP - Henri Mondor Hospital, Paris, France, ⁸15Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁰Dijon, Dijon, France, ¹¹Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Internal Medicine, CHU - Reims University, Reims, France, ¹⁵Internal Medicine, Paris Descartes Université - APHP, paris, France, ¹⁶Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ¹⁷Internal Medicine, Université Tours - CHU, Tours, France, ¹⁸Internal Medicine, CH Annecy, Annecy, France, ¹⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁰Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Background/Purpose: Dermatomyositis (DM) is a heterogenous group of diseases ranging from skin limited disorders to non-specific auto-immune diseases with patients suffering from additional extra-cutaneous manifestations.…
Abstract Number: 1734 • 2018 ACR/ARHP Annual Meeting
Association of Short-Term Longitudinal Changes in Clinical and Physiologic Variables with Overall Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Vincent Sobanski¹, Jeska de Vries-Bouwstra², Anna-Maria Hoffmann-Vold³, Dörte Huscher⁴, Margarida Alves⁵, Marco Matucci-Cerinic⁶, Gabriela Riemekasten⁷, Mengtao Li⁸, Gabriele Valentini⁹, László Czirják¹⁰, Otylia Kowal-Bielecka¹¹, Yannick Allanore¹², Nils Schoof⁵ and Oliver Distler¹³, ¹Department of Internal Medicine and Clinical Immunology, University of Lille, Lille, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo University Hospital, Oslo, Norway, ⁴Charité – Universitaetsmedizin Berlin and Berlin Institute of Health, Berlin, Germany, ⁵Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁷Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ⁸Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁹Department of Rheumatology, Second University of Naples, Napoli, Italy, ¹⁰Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ¹¹Department of Rheumatology and Internal Medicine, Medical University of Białystok, Białystok, Poland, ¹²Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ¹³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of morbidity and mortality in patients with SSc. However, the impact of changes in…
Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…
Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Masataka Kuwana², Ning Li³, Julio Charles⁴, Faye N. Hant⁵, Galina S. Bogatkevich⁶, Tanjina Akter⁶, Michael Roth⁷, Hyun J. Grace Kim⁸, Jonathan Goldin⁹, Dinesh Khanna¹⁰, Philip J. Clements¹¹, Daniel E. Furst⁷, Robert Elashoff¹², Rick Silver¹³ and Shervin Assassi¹⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of California, Los Angeles, Los Angeles, CA, ¹²University of California, Los Angeles, Los Angeles, CA, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
Abstract Number: 2015 • 2018 ACR/ARHP Annual Meeting
Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies
Sara Sabbagh¹, Iago Pinal-Fernandez¹, Takayuki Kishi², Ira N. Targoff³, Frederick W. Miller², Lisa G. Rider² and Andrew Mammen^1,4, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Environmental Health Sciences, National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA) found in adult and juvenile idiopathic inflammatory myopathies (JIIM) often confer a specific disease phenotype.…
Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting
Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Osman Bhatty¹, Rouhin Sen¹, Douglas Moore² and Joseph Nahas³, ¹Department of Medicine, CHI Creighton University Medical Center, Omaha, NE, ²Department of Pulmonary/Critical Care, CHI Creighton University Medical Center, Omaha, NE, ³Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…
Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Dinesh Khanna², Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Lynette Keyes-Elstein⁴, Ashley Pinckney⁴, Ellen Goldmuntz⁵, Robert Elashoff⁶ and Keith Sullivan⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵NIAID, NIH, Bethesda, MD, ⁶University of California, Los Angeles, Los Angeles, CA, ⁷Duke University, Durham, NC
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].